Pembrolizumab with Chemoradiation as Treatment for Muscle-invasive Bladder Cancer: Analysis of Safety and Efficacy of the PCR-MIB Phase 2 Clinical Trial (ANZUP 1502)

James, 2012, Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer, N Engl J Med, 366, 1477, 10.1056/NEJMoa1106106 Hall, 2022, Chemoradiotherapy in muscle-invasive bladder cancer: 10-yr follow-up of the phase 3 randomised controlled BC2001 trial, Eur Urol, 82, 273, 10.1016/j.eururo.2022.04.017 Zlotta, 2023, Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis, Lancet Oncol, 24, 669, 10.1016/S1470-2045(23)00170-5 Bellmunt, 2017, Pembrolizumab as second-line therapy for advanced urothelial carcinoma, N Engl J Med, 376, 1015, 10.1056/NEJMoa1613683 Powles, 2020, Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma, N Engl J Med, 383, 1218, 10.1056/NEJMoa2002788 Powles, 2018, A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in muscle invasive bladder cancer (ABACUS), J Clin Oncol, 36, 4506, 10.1200/JCO.2018.36.15_suppl.4506 Necchi, 2018, Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study, J Clin Oncol, 36, 3353, 10.1200/JCO.18.01148 Filatenkov, 2015, Ablative tumor radiation can change the tumor immune cell microenvironment to induce durable complete remissions, Clin Cancer Res, 21, 3727, 10.1158/1078-0432.CCR-14-2824 Wennerberg, 2020, CD73 Blockade promotes dendritic cell infiltration of irradiated tumors and tumor rejection, Cancer Immunol Res, 8, 465, 10.1158/2326-6066.CIR-19-0449 Lim, 2014, Type I interferons induced by radiation therapy mediate recruitment and effector function of CD8+ T cells, Cancer Immunol Immunother, 63, 259, 10.1007/s00262-013-1506-7 Serre, 2016, Mathematical modeling of cancer immunotherapy and its synergy with radiotherapy modeling of radioimmunotherapy, Cancer Res, 76, 4931, 10.1158/0008-5472.CAN-15-3567 Sharabi, 2015, Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy, Lancet Oncol, 16, e498, 10.1016/S1470-2045(15)00007-8 Marciscano, 2018, Elective nodal irradiation attenuates the combinatorial efficacy of stereotactic radiation therapy and immunotherapy nodal irradiation attenuates synergy with immunotherapy, Clin Cancer Res, 24, 5058, 10.1158/1078-0432.CCR-17-3427 Gill, 2022, Clinical evidence for synergy between immunotherapy and radiotherapy (SITAR), J Med Imaging Radiat Oncol, 66, 881, 10.1111/1754-9485.13441 Abuodeh, 2016, Systematic review of case reports on the abscopal effect, Curr Probl Cancer, 40, 25, 10.1016/j.currproblcancer.2015.10.001 Spigel, 2022, Five-year survival outcomes from the PACIFIC trial: Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer, J Clin Oncol, 40, 1301, 10.1200/JCO.21.01308 Clopper, 1934, The use of confidence or fiducial limits illustrated in the case of the binomial, Biometrika, 26, 404, 10.1093/biomet/26.4.404 Balar, 2021, Pembrolizumab (pembro) in combination with gemcitabine (Gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial cancer of the bladder (MIBC): a multicenter phase 2 trial, J Clin Oncol, 39, 4504, 10.1200/JCO.2021.39.15_suppl.4504 Marcq, 2021, Phase 1 trial of atezolizumab plus trimodal therapy in patients with localized muscle-invasive bladder cancer, Int J Radiat Oncol, 110, 738, 10.1016/j.ijrobp.2020.12.033 de Ruiter, 2022, Phase 1 study of chemoradiotherapy combined with nivolumab ± ipilimumab for the curative treatment of muscle-invasive bladder cancer, Eur Urol, 82, 518, 10.1016/j.eururo.2022.07.009 Singh, 2021, INTACT (S/N1806) phase III randomized trial of concurrent chemoradiotherapy with or without atezolizumab in localized muscle-invasive bladder cancer: safety update on first 73 patients, J Clin Oncol, 39, 428, 10.1200/JCO.2021.39.6_suppl.428 Tree, 2018, Dose-limiting urinary toxicity with pembrolizumab combined with weekly hypofractionated radiation therapy in bladder cancer, Int J Radiat Oncol Biol Phys, 101, 1168, 10.1016/j.ijrobp.2018.04.070 Gogna, 2006, Efficacy and tolerability of concurrent weekly low dose cisplatin during radiation treatment of localised muscle invasive bladder transitional cell carcinoma: a report of two sequential phase II studies from the Trans Tasman Radiation Oncology Group, Radiother Oncol, 81, 9, 10.1016/j.radonc.2006.09.001 Balar, 2020, Phase III study of pembrolizumab (Pembro) plus chemoradiotherapy (CRT) versus CRT alone for patients (Pts) with muscle-invasive bladder cancer (MIBC): KEYNOTE-992, J Clin Oncol, 38, TPS509, 10.1200/JCO.2020.38.15_suppl.TPS5093 Canadian Cancer Trials Group. A randomized phase II trial assessing trimodality therapy with or without adjuvant durvalumab to treat patients with muscle-invasive bladder cancer. 2022. https://clinicaltrials.gov/ct2/show/NCT03768570. Hoskin, 2010, Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma, J Clin Oncol, 28, 4912, 10.1200/JCO.2010.28.4950 James, 2022, TUXEDO: a phase I/II trial of cetuximab with chemoradiotherapy in muscle-invasive bladder cancer, BJU Int, 131, 63, 10.1111/bju.15864 Machiels, 2022, LBA5 Primary results of the phase III KEYNOTE-412 study: pembrolizumab (pembro) with chemoradiation therapy (CRT) vs placebo plus CRT for locally advanced (LA) head and neck squamous cell carcinoma (HNSCC), Ann Oncol, 33, S1399, 10.1016/j.annonc.2022.08.029 Bajorin, 2021, Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma, N Engl J Med, 384, 2102, 10.1056/NEJMoa2034442 Powles, 2021, Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial, Lancet Oncol, 22, 931, 10.1016/S1470-2045(21)00152-2 Galsky, 2020, Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial, Lancet, 395, 1547, 10.1016/S0140-6736(20)30230-0 van Dijk, 2020, Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial, Nat Med, 26, 1839, 10.1038/s41591-020-1085-z Cathomas, 2020, Perioperative chemoimmunotherapy with durvalumab (Durva) in combination with cisplatin/gemcitabine (Cis/Gem) for operable muscle-invasive urothelial carcinoma (MIUC): preplanned interim analysis of a single-arm phase II trial (SAKK 06/17), J Clin Oncol, 38, 499, 10.1200/JCO.2020.38.6_suppl.499 Hoimes, 2020, Phase Ib/II neoadjuvant (N-) pembrolizumab (P) and chemotherapy for locally advanced urothelial cancer (laUC): final results from the cisplatin (C)-eligible cohort of HCRN GU14-188, J Clin Oncol, 38, 5047, 10.1200/JCO.2020.38.15_suppl.5047 Gupta, 2020, Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy, J Clin Oncol, 38, 439, 10.1200/JCO.2020.38.6_suppl.439 Galsky, 2021, 658MO Cisplatin (cis)-related immunomodulation and efficacy with atezolizumab (atezo) + cis- vs carboplatin (carbo)-based chemotherapy (chemo) in metastatic urothelial cancer (mUC), Ann Oncol, 32, S682, 10.1016/j.annonc.2021.08.054 Darragh, 2022, Elective nodal irradiation mitigates local and systemic immunity generated by combination radiation and immunotherapy in head and neck tumors, Nat Commun, 13, 7015, 10.1038/s41467-022-34676-w